(Q36674172)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

review article

1 reference

title

Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Raja S Bobba

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Karen Beattie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Bill Parkinson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Jonathan D Adachi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

language of work or name

1 reference

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

1133-1152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17147460%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00002018-200629120-00005

22 December 2019

exact match

0 references

cites work

Zoledronic Acid and renal toxicity: data from French adverse effect reporting database

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200629120-00005

Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200629120-00005

Patients receiving intravenous bisphosphonates should avoid invasive dental procedures

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200629120-00005

An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover

21 January 2018

1 reference

12 December 2020

Safety and convenience of a 15-minute infusion of zoledronic acid

1 reference

12 December 2020

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

12 December 2020

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

12 December 2020

A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease

1 reference

12 December 2020

Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study

1 reference

12 December 2020

Alendronate and naproxen are synergistic for development of gastric ulcers

1 reference

12 December 2020

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

1 reference

12 December 2020

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

12 December 2020

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

12 December 2020

Zoledronic acid: a new parenteral bisphosphonate

1 reference

12 December 2020

A medication use evaluation of alendronate: compliance with administration guidelines.

1 reference

12 December 2020

[Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]

1 reference

12 December 2020

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

12 December 2020

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International

1 reference

12 December 2020

Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.

1 reference

12 December 2020

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

1 reference

12 December 2020

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe

1 reference

12 December 2020

Diagnosis of osteoporosis and assessment of fracture risk

1 reference

12 December 2020

Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

1 reference

12 December 2020

Efficacy and safety of ibandronate given by intravenous injection once every 3 months

1 reference

12 December 2020

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

12 December 2020

Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia

1 reference

12 December 2020

Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women

1 reference

12 December 2020

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

12 December 2020

Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review

1 reference

12 December 2020

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

12 December 2020

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials

1 reference

12 December 2020

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

1 reference

12 December 2020

Extended safety profile of oral clodronate after long-term use in primary breast cancer patients

1 reference

12 December 2020

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

1 reference

12 December 2020

The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study

1 reference

12 December 2020

Osteonecrosis of the jaw and bisphosphonates

1 reference

12 December 2020

Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy

1 reference

12 December 2020

Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates

1 reference

12 December 2020

Renal safety of ibandronate

1 reference

12 December 2020

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

1 reference

12 December 2020

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

1 reference

12 December 2020

Bisphosphonates in the management of metastatic prostate cancer

1 reference

12 December 2020

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

12 December 2020

Alendronate and risedronate: reports of severe bone, joint, and muscle pain

1 reference

12 December 2020

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

1 reference

12 December 2020

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

12 December 2020

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Bisphosphonates and bone necrosis

1 reference

12 December 2020

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

1 reference

12 December 2020

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

12 December 2020

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis

1 reference

12 December 2020

[Osteoporosis and osteoarthritis--is there really an inverse relation?]

1 reference

12 December 2020

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial

1 reference

12 December 2020

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.

1 reference

12 December 2020

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

1 reference

12 December 2020

Clodronate induced uveitis

1 reference

12 December 2020

The issue of renal safety of zoledronic acid from a nephrologist's point of view.

1 reference

12 December 2020

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

1 reference

12 December 2020

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

1 reference

12 December 2020

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study

1 reference

12 December 2020

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

12 December 2020

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

1 reference

12 December 2020

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study

1 reference

12 December 2020

Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group

1 reference

12 December 2020

Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study

1 reference

12 December 2020

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

1 reference

12 December 2020

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis

1 reference

12 December 2020

Renal secretion of diphosphonates in rats

1 reference

12 December 2020

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

1 reference

12 December 2020